MET and breast carcinoma: A potential mechanism of tumor resistance against RTK inhibitors was found in non small-cell lung cancer (NSCLC) and HER2-positive breast cancer, where tumors became resistant to EGFR inhibition as a consequence of MET gene amplification[19,20].